2. Signaling Pathways
  3. GPCR/G Protein
  4. GLP Receptor

GLP Receptor

GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3491
    Pegloxenatide
    		Agonist
    Pegloxenatide is a glucagon-like peptide-1 receptor (GLP-1 RA) agonist. Pegloxenatide can be used for type 2 diabetes research.
    Pegloxenatide
  • HY-P1230
    HAEGT
    		98.86%
    HAEGT is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity.
    HAEGT
  • HY-108795
    Albiglutide fragment
    		Agonist 98.79%
    Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies.
    Albiglutide fragment
  • HY-P10032
    NN1177
    		Agonist 99.77%
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
    NN1177
  • HY-P10269
    Bofanglutide
    		Agonist 99.26%
    Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC50 of 0.677 nM. GZR18 ameliorates type 2 diabetes.
    Bofanglutide
  • HY-P10302
    GLP-1R/GIPR agonist-1
    		Agonist
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
    GLP-1R/GIPR agonist-1
  • HY-N7426
    3-Deoxyglucosone
    3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.
    3-Deoxyglucosone
  • HY-P10031
    SAR441255
    		Agonist 99.77%
    SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys.
    SAR441255
  • HY-163996
    DD202-114
    		Agonist 98.47%
    DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity.
    DD202-114
  • HY-139276
    Pal-Glu(OSu)-OH
    		≥98.0%
    Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research.
    Pal-Glu(OSu)-OH
  • HY-P10716
    Exendin-P5
    		Activator
    Exendin-P5 is a selective agonist that targets the GLP-1R. Exendin-P5 promotes rapid activation of G proteins by transient interactions with the transmembrane domain of GLP-1R, enhancing its potency in G protein-mediated signaling and accelerating cAMP production. This mechanism suggests the potential application of Exendin-P5 in the study of metabolic diseases.
    Exendin-P5
  • HY-P1445
    HAEGTFTSDVSSYLE
    		98.16%
    HAEGTFTSDVSSYLE is a polypeptide from patent CN 102920658 B. GLP-I analog contains the sequence.
    HAEGTFTSDVSSYLE
  • HY-P990967
    Sonefpeglutide
    HY-P990967 is an GLP1R-targeting human antibody.
    Sonefpeglutide
  • HY-P5161
    FC382K10W15
    		Agonist
    FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research.
    FC382K10W15
  • HY-P10318
    SHR-2042
    		Antagonist
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency.
    SHR-2042
  • HY-143312C
    (S)-V-0219
    		Modulator
    (S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice.
    (S)-V-0219
  • HY-162306
    GLP-1R agonist 18
    		Agonist
    GLP-1R agonist 18 (example 117) is an agonist for GLP-1R with an EC50 of 0.044 nM.
    GLP-1R agonist 18
  • HY-P10591
    Olatorepatide
    		Agonist
    Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect.
    Olatorepatide
  • HY-P0264A
    Exendin(9-39) amide acetate
    		Antagonist
    Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research.
    Exendin(9-39) amide acetate
  • HY-147628
    GLP-1R agonist 15
    		Agonist
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist.
    GLP-1R agonist 15
Cat. No. Product Name / Synonyms Application Reactivity